Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-08-11Clinical Trial Update: PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating a DNA damage response inhibitor with or without anti-PD-L1 immunotherapy in patients with neoadjuvant-trea…
-
CLINICAL_TRIALS research · 2025-08-11Clinical Trial Update: A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors [EARLY_Phase 1]
Phase 0 multicenter study evaluating pharmacodynamic effects of intratumoral microdosing with PBA-0111 in solid tumors; the trial is current…
-
CLINICAL_TRIALS research · 2025-08-07Clinical Trial Update: BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer [Phase 2]
Biocad's BCD-236 is being studied in combination with chemotherapy for relapsed and/or metastatic triple-negative breast cancer in a Phase 2…
-
CLINICAL_TRIALS research · 2025-08-05Clinical Trial Update: Triple Negative Breast Cancer and Celecoxib. Pilot Study [Phase 2]
This is a Phase 2 pilot clinical trial evaluating celecoxib in combination for triple-negative breast cancer and is currently recruiting.
-
CLINICAL_TRIALS research · 2025-08-05Clinical Trial Update: Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC [Phase 2]
A prospective multicenter Phase 2 single-arm trial evaluating AK112 plus nab-paclitaxel and carboplatin as neoadjuvant therapy for triple-ne…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-08-03Clinical Trial Update: A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC). [Phase 2]
Phase 2 randomized neoadjuvant trial evaluating JS004 plus toripalimab with chemotherapy versus toripalimab with chemotherapy and chemothera…
-
CLINICAL_TRIALS research · 2025-08-01Clinical Trial Update: Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative [NA]
This clinical trial update describes using molecular testing and imaging to improve response in patients with stage I-III triple-negative br…
-
CLINICAL_TRIALS research · 2025-07-30Clinical Trial Update: DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs [Phase 2]
A Phase 2 trial of datopotamab deruxtecan (DATO-BASE) for breast cancer with brain metastases is currently recruiting.
-
CLINICAL_TRIALS research · 2025-07-29Clinical Trial Update: Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer [NA]
Clinical trial update on zoledronic acid combined with the EC-T chemotherapy regimen for metastatic triple-negative breast cancer; the study…
-
CLINICAL_TRIALS research · 2025-07-29Clinical Trial Update: Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC [Phase 2]
A Phase 2 clinical trial update evaluating Sacituzumab tirumotecan for neoadjuvant therapy in early-stage triple-negative breast cancer; the…
-
CLINICAL_TRIALS research · 2025-07-25Clinical Trial Update: Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) [Phase 1, Phase 2]
A Phase 1/2 START trial evaluating the combination of selinexor and talazoparib in advanced refractory solid tumors and triple-negative brea…
-
CLINICAL_TRIALS research · 2025-07-25Clinical Trial Update: Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial testing pembrolizumab combined with ADG106 for advanced solid tumors and triple-negative breast cancer is c…
-
CLINICAL_TRIALS research · 2025-07-18Clinical Trial Update: PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer. [Phase 2]
Phase 2 clinical trial evaluating PSMA-PET/CT to assess PSMA expression in patients with progressive triple-negative breast cancer; recruitm…
-
CLINICAL_TRIALS research · 2025-07-18Clinical Trial Update: Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
Real-world study evaluating post-resistance treatment strategies after CDK4/6 inhibitors, PIK3CA inhibitors, or trastuzumab deruxtecan in ad…
-
CLINICAL_TRIALS research · 2025-07-16Clinical Trial Update: A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer [Phase 3]
A Phase III, multicenter randomized open-label trial is evaluating a PD-1 inhibitor with anti-vascular therapy and anthracycline/taxane-base…
-
CLINICAL_TRIALS research · 2025-07-14Clinical Trial Update: Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies [Phase 1, Phase 2]
SPEDOX-6, a single protein encapsulated doxorubicin, is being studied in Phase 1/2 trials for several advanced cancers and is currently recr…
-
CLINICAL_TRIALS research · 2025-07-11Clinical Trial Update: Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer [Phase 3]
Phase 3 clinical trial update assessing an adjuvant treatment regimen for triple-negative breast cancer, involving initial EC-directed thera…
-
CLINICAL_TRIALS research · 2025-07-10Clinical Trial Update: Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer [Phase 2]
This document provides an update on a Phase 2 neoadjuvant trial of weekly carboplatin plus paclitaxel for triple-negative breast cancer; the…
-
CLINICAL_TRIALS research · 2025-07-09Clinical Trial Update: Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC) [NA]
This clinical trial investigates using imatinib to convert triple-negative breast cancer into estrogen receptor–positive breast cancer, and …
-
CLINICAL_TRIALS research · 2025-07-08Clinical Trial Update: Role of the Immune Environment in Response to Therapy in Breast Cancer
A clinical trial update from Penn Medicine describes a study on how the immune environment influences response to therapy in breast cancer, …
-
CLINICAL_TRIALS research · 2025-07-01Clinical Trial Update: Trop-2 Targeted PET Probes in Advanced TNBC [NA]
A clinical trial update indicates Trop-2 targeted PET probes are being investigated for advanced triple-negative breast cancer and the study…
-
CLINICAL_TRIALS research · 2025-07-01Clinical Trial Update: Optimal Combination of Adjuvant Radiotherapy and Immunotherapy for Breast Cancer
This update covers a clinical trial evaluating the optimal combination of adjuvant radiotherapy and immunotherapy for breast cancer, includi…
-
CLINICAL_TRIALS research · 2025-06-25Clinical Trial Update: Personalized Vaccine for TNBC Immunotherapy [Phase 1]
A Phase 1 clinical trial evaluating a personalized vaccine for triple-negative breast cancer is listed as not yet recruiting.
-
CLINICAL_TRIALS research · 2025-06-24Clinical Trial Update: HS-10502 Combination Treatment in Patients With Advanced Solid Tumors [Phase 1]
A Phase 1 clinical trial update for HS-10502 in patients with advanced solid tumors, including recurrent ovarian cancer and HER2-negative br…
-
CLINICAL_TRIALS research · 2025-06-23Clinical Trial Update: SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer [Phase 2]
A Phase 2 trial evaluating SHR-A2102 in combination with Adebrelimab as neoadjuvant therapy for early-stage triple-negative breast cancer; t…